The Breast Friends Podcast

Breast oncology is moving fast, and ESR1 mutations are now at the center of a major shift in endocrine therapy.In Episode 10, Dr. Jason Mouabbi and Dr. Paolo Tarantino break down how ctDNA, oral SERDs, new combinations, and emerging endocrine therapies are changing treatment decisions in HR-positive breast cancer. They also tackle one of the biggest questions in the field: when should clinicians act on molecular progression before it shows up on scans?Topics discussed:• Why ESR1 mutations matter in endocrine resistance• SERENA-6 and ctDNA-guided treatment switching• Oral SERDs in monotherapy and combination• EMBER-3, ELEVATE, and evERA• Balancing efficacy, toxicity, and treatment sequencing• Emerging therapies beyond SERDs, including CERANs and next-generation SERMs• What comes next for endocrine therapy in breast cancer🎙️ Hosted by Dr. Jason Mouabbi & Dr. Paolo Tarantino🎧 Watch the full episode and follow The Breast Friends Podcast for more conversations on the latest in breast oncology - https://youtu.be/5Z7a3HkDsG4#BreastFriends #JasonMouabbi #PaoloTarantino #BreastCancer #ESR1 #HRPositive #OralSERD #ctDNA #EndocrineTherapy #PrecisionOncology #MedicalOncology #CommunityHealthMedia

What does it mean to treat the person, not just the cancer?In Episode 9 of The Breast Friends Podcast, Dr. Jason Mouabbi and Dr. Paolo Tarantino are joined by Prof. Gabriella Pravettoni to explore the human side of cancer care, from psycho-oncology and quality of life to shared decision-making and the evolving role of AI.Topics discussed:• Psycho-oncology and patient-centered cancer care• Quality of life and individual patient priorities• Shared decision-making and building trust• The impact of family and culture on cancer care• AI and the changing patient-physician relationship🎙️ Hosted by Drs. Jason A. Mouabbi & Paolo Tarantino▶️ Watch on YouTube - https://youtu.be/J88wBHM-AEY🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox, and Amazon Music - https://linkin.bio/breastfriendspodcast#BreastFriends #GabriellaPravettoni #JasonMouabbi #PaoloTarantino #PsychoOncology #PatientCenteredCare #SharedDecisionMaking #QualityOfLife #BreastCancer #CommunityHealthMedia

What were the most practice-changing breast cancer studies and updates presented at ASCO 2026?In this episode of Breast Friends, Dr. Jason Mouabbi and Dr. Paolo Tarantino share their biggest takeaways from ASCO 2026, discussing the clinical trials, FDA approvals, and emerging therapies they believe will have the greatest impact on breast cancer care.From HR-positive and HER2-positive disease, to triple-negative breast cancer, the conversation explores how new evidence is changing treatment decisions today—and what clinicians should be watching next.Topics discussed:• DESTINY-Breast09 and first-line HER2-positive metastatic breast cancer• SERENA-6 and ctDNA-guided treatment switching• OPTIMA and Prosigna-guided chemotherapy de-escalation• Giredestrant updates• Gedatolisib and the VIKTORIA-1 trial• Oral SERDs and the future of endocrine therapy• ADCs for metastatic triple-negative breast cancer• Iza-Bren and the PANKU-Breast02 trial• GLP-1 receptor agonists and breast cancer outcomes• The NHS-Galleri trial• Biomarkers, precision oncology, and treatment sequencing• Looking ahead to ESMO 2026 and SABCS🎙️ Hosted by Drs. Jason A. Mouabbi & Paolo Tarantino▶️ Watch on YouTube - https://youtu.be/BZC5_C3KyjE🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music - https://linkin.bio/breastfriendspodcastThe Breast Friends Podcast is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time.#BreastFriends #JasonMouabbi #PaoloTarantino #ASCO2026 #BreastCancer #MedicalOncology #HER2Positive #TripleNegativeBreastCancer #HRPositive #PrecisionOncology #CommunityHealthMedia

How did liquid biopsy become one of the most important tools in modern oncology?In Episode 7 of The Breast Friends Podcast, Dr. Jason Mouabbi and Dr. Paolo Tarantino are joined by Dr. Daniel Hayes, Past President of ASCO and one of the pioneers behind tumor markers and liquid biopsy in breast cancer.From the mid-1980s breakthrough clinical discovery of CA 15-3 to the cutting-edge evolution of circulating tumor cells (CTCs), ctDNA, MRD, and multi-cancer early detection (MCED), Dr. Hayes shares the captivating behind-the-scenes stories, scientific milestones, and lessons that have shaped decades of breast cancer research.This conversation is more than an oncology history lesson. It's a deep dive into the future of precision medicine, the reality of tumor heterogeneity, and the mystery of cancer dormancy that will define the next generation of cancer care.🎙️ Hosted by Drs. Jason A. Mouabbi & Paolo Tarantino▶️ Watch on YouTube - https://youtu.be/PvguD4bXN-E🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox, and Amazon Music - https://linkin.bio/breastfriendspodcast📺 As Mentioned in the Episode:Watch the historic interview featuring Dr. Daniel Hayes, Dr. Lawrence Einhorn, and John Cleland, the first patient ever cured of metastatic testicular cancer with platinum combination therapy: https://youtu.be/mKBQDSMInuI?si=YGvwlS-UfXlNvloPThe Breast Friends Podcast is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time.#BreastCancer #Oncology #LiquidBiopsy #ctDNA #CTCs #PrecisionOncology #CancerResearch #MedicalOncology #ASCO #OncologyPodcast #MedEd

The HER2-positive revolution isn't coming. It's here.In Episode 6 of The Breast Friends Podcast, Dr. Jason Mouabbi and Dr. Paolo Tarantino unpack the practice-changing data emerging from ESMO Breast 2026.From DESTINY-Breast11 and DESTINY-Breast05 to the growing role of HER2DX, ctDNA, MRI-guided treatment adaptation, and chemotherapy-free strategies, this conversation explores a fundamental shift in breast oncology: moving from treating every patient the same to delivering truly personalized care.Can we safely eliminate carboplatin?Can biomarkers tell us who needs less treatment?Is a chemotherapy-free future finally a reality for certain patients?The future of HER2-positive breast cancer is being written right now.🎙️ Hosted by Drs. Jason A. Mouabbi & Paolo Tarantino▶️ Watch on YouTube - https://youtu.be/WrvmVGEgoIA🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music#BreastCancer #HER2Positive #Oncology #OncologyPodcast #ESMOBreast #CancerResearch #ClinicalTrials #PrecisionMedicine #MedicalOncology #MedEd #Enhertu #TDXd

What shaped modern breast oncology and what comes next?From the pioneering HER2 breakthroughs to the recent innovation of ADCs and oral SERDs, Dr. Rugo provides a masterclass on the therapies that are changing the standard of care. The discussion also looks ahead, exploring the clinical utility of ctDNA monitoring and the critical importance of preserving quality of life in the metastatic setting.From HER2 breakthroughs and ADC innovation to oral SERDs, ctDNA monitoring, quality of life, and the future of metastatic breast cancer care, this conversation is a masterclass in where the field has been and where it’s heading next.This is oncology history, innovation, and the future all in one conversation.🎙️ Hosted by Drs. Jason A. Mouabbi & Paolo Tarantino👤 Featuring Dr. Hope Rugo▶️ Watch on YouTube - https://youtu.be/IGbXzLpE-LY🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music#BreastCancer #Oncology #OncologyPodcast #HopeRugo #CancerResearch #ClinicalTrials #PrecisionMedicine #MedicalOncology #MedEd #ADC

What does the future of breast oncology look like?In Episode 4, Dr. Jason Mouabbi and Dr. Paolo Tarantino are joined by Professor Giuseppe Curigliano, Professor of Medical Oncology at the University of Milano, Head of the Experimental Therapeutics Program at the European Institute of Oncology, ESMO President-Elect, and Young Science Talent Scout, to forecast the next decade of breast cancer care.This conversation looks beyond current standards to the next frontier of breast oncology—from the evolution of ADCs and ctDNA to the emerging roles of bispecifics, radioligand therapy, and cancer vaccines.We’re mapping out where the science is heading and how it will redefine precision medicine in breast cancer!🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music#BreastCancer #Oncology #OncologyPodcast #CancerResearch #ClinicalTrials #PrecisionMedicine #MedEd #MedicalOncology #ESMO #CancerInnovation

👉 Cast your vote here: https://www.tinyurl.com/breastfriendsmadnessIt’s March Madness, the Breast Friends Madness way!In Episode 3, Dr. Jason Mouabbi and Dr. Paolo Tarantino are hitting the court to break down the heavy hitters of 2025 using our "Breast Friends Madness" bracket.Among the featured lineups are studies ranging from the practice-changing results of the DESTINY-Breast trials to the strategic shifts in SERENA-6, monarchE, and ASCENT-04. We’re scouting the data officially rewriting the playbook for HER2+, TNBC, and HR+ care.EVERY study in this bracket is a WIN for our patients. Let’s get ready to highlight the trials moving the field forward.▶️ Watch on YouTube🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox & Amazon Music#BreastCancer #Oncology #OncologyPodcast #CancerResearch #ClinicalTrials #HER2Positive #TripleNegativeBreastCancer #MedEd #MedicalOncology

What’s coming in 2026 is about to reshape breast oncology.In Episode 2, Dr. Jason Mouabbi and Dr. Paolo Tarantino go beyond published data to tackle the tough questions about what's next. They break down the evolving landscape of KEYNOTE-756, the rise of oral SERDs in the first line, and the role of HER2DX. From T-DXd in early disease and CNS risk in HER2+, to the promise of improving outcomes in triple-negative breast cancer, they are laying out the roadmap for the future of care.The landscape is moving fast. Listen in as we prepare for the next wave of practice-changing data.▶️ Watch on YouTube - https://youtu.be/Skt3jGMBncM🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox, & Amazon Music#BreastCancer #Oncology #OncologyPodcast #ClinicalTrials #CancerResearch #HER2Positive #TripleNegative #OralSERD #ADCs #MedicalOncology #MedEd #CancerCare

It’s finally here. 🎙️The first full episode of The Breast Friends Podcast is live. Join Dr. Jason A. Mouabbi and Dr. Paolo Tarantino for a comprehensive look at the rapidly evolving breast cancer landscape. From new endocrine backbones to the "unprecedented" data emerging in the ADC space, they are debating the breakthroughs that are changing the way we practice medicine today.Beyond the statistics, this episode focuses on the "art" of clinical selection. You’ll hear an honest discussion on therapy sequencing, balancing toxicities, and navigating complex trial data—all while ensuring treatment is tailored to each patient’s unique needs and daily reality.Real data. Hard questions. And yes—plenty of fun along the way.#BreastCancer #OncologyPodcast #CancerCare #MedicalOncology #BreastCancerResearch #MedEd #ClinicalOncology #PhysicianVoices